CClinicalTrials.gg
RecruitingNCT06202404Updated Feb 9, 2024

Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model

An observational study in Metastasis and Predictive Cancer Model, sponsored by Fudan University. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by Fudan University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
166
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A pre-metastatic target organ/primary lesion fusion radiomics model was developed based on the "soil-seed" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ/primary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.

Read the detailed description

Metastasis is an important biological feature of malignant tumors, and it is also the main factor affecting the outcome of cancer patients. The direct death of most cancer patients is the mass effect of metastatic lesions or the loss of metastatic target organ function. Therefore, it has become one of the urgent and arduous tasks in the field of oncology to explore the pathophysiological mechanism of malignant tumor metastasis and find new targets to form new methods for the early diagnosis and treatment of tumor metastasis.

Tumor metastasis is a continuous and gradual process. Tumor cells in the primary tumor proliferated, tumor cells shed from the primary tumor, invaded the basement membrane, invaded blood vessels, lymphatic vessels or body cavity, and migrated to another site or organ with the blood flow and lymph flow. Tumor cells adhered to the capillaries of the target organ, penetrated the blood vessels to form micrometastases, cell proliferation and produced new blood vessels, and formed secondary tumors of the same type as the primary tumor. They can invade and metastasize again. In the process of metastasis, gene mutations and subsequent changes in the immunogenicity of tumor cells promote the formation of local tumor tissue inhibitory microenvironment, which suppresses the host immune system and leads to tumor metastasis.

Previous studies have found that tumor metastasis has Organ specificity, called "Organ-tropism". That is, different types of tumors tend to metastasize to different organs. For example, lung cancer often metastasizes to the brain, colorectal cancer and pancreatic cancer commonly metastasize to the liver, breast cancer and prostate cancer commonly metastasize to the bone, and so on. Therefore, Stephen Paget, a British pathologist, put forward and elaborated his "seed and soil theory" more than a hundred years ago, advocating that metastasis requires the spread of tumor cells, that is, "seeds", and the ideal environment for receiving organs, that is, "fertile soil". He proposed in this theory that successful metastasis to distant organs requires not only tumor cells with metastatic potential (seeds) but also a suitable host organ (soil). During tumor progression, the composition and phenotypic types of immune cells in the tumor microenvironment are shaped by both malignant cells and the niche of adjacent tissues. Metastatic tumors (seeds) will retain genetic characteristics when they are transferred to different organ-specific tissue environments (soil). It is not enough for tumor cells to reach a certain organ tissue, but also requires the coordination between tumor cells (seeds) and organ microenvironment (soil) to plant and grow in a suitable environment (soil) and become metastatic foci. In the "seed and soil theory", the intrinsic characteristics of seeds have been proved to affect various key transfer processes. On the other hand, few studies have focused on the relationship between the intrinsic characteristics of soil (target organ) and the formation of malignant tumor metastasis, one of the main reasons is that it is often not ethical to conduct invasive research on the target organ of patients without metastasis.

Radiomics is an emerging field, which develops new biomarkers through quantitative analysis of imaging examination images of patients, which can study and analyze the potential pathophysiological characteristics of regions of interest in a non-invasive way. Previous studies have shown that radiomics studies of seeds (primary tumors) can predict metastasis of many malignant tumors, which establishes radiomics evidence for the "seed and soil" theory from the perspective of seeds. However, radiomics studies from the perspective of soil (the target organ for metastasis) are rare. Taking the brain metastases of lung cancer as an example, most existing radiomics studies using brain imaging information only evaluate the regions where brain metastases have occurred. Considering that radiomics can also extract biological features from target organs that have not yet metastasized, our group has found that radiomics analysis of pretreatment brain MRI images of lung cancer patients without baseline brain metastasis can effectively predict the probability of brain metastasis in a certain period of time. This study also revealed for the first time that the target organ without metastasis (soil) also plays a key role in the occurrence of malignant tumor metastasis.

The results of this study also suggest that the malignancy prediction model derived from radiomics could be a promising tool for screening patients at high risk of tumor metastasis. Integrated risk prediction models that take into account seed and soil characteristics may help guide clinical practice (e.g., more rigorous monitoring of high-risk patients or the use of more intensive systemic treatment).

In conclusion, it is necessary to further explore the applicability of this seed and soil theory-based radiomics model for cancer prediction to verify its universality and clinical application prospects. In this study, we will collect imaging information of patients' baseline primary lesions and potential metastatic target organs in a variety of common tumors (lung cancer, colorectal cancer, breast cancer, etc.). To explore the performance of the "seed and soil" radiomics model in predicting cancer metastasis patterns (brain metastasis of lung cancer, liver metastasis of colorectal cancer, lung metastasis of breast cancer), in order to establish a non-invasive, cost-effective and effective radiomics prediction model for distinguishing "high risk" and "low risk" cancer metastasis in corresponding cancer types. To provide a theoretical basis for the further formation of individualized diagnosis and treatment standards for patients with malignant tumors.

02

Conditions studied

  • Metastasis
  • Predictive Cancer Model

Browse trials for

Keywords

  • metastasis
  • radiomics
  • seed and soil theory
03

In context

Neoplasm Metastasis

3,517 studies on the registry are indexed under Neoplasm Metastasis; 884 are open to participants now.

This study's planned enrollment of 166 is above the median of 121 across 594 observational studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Fudan University is the lead sponsor of 1,271 studies on the registry; 624 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study was a prospective observational study. According to the inclusion and exclusion criteria, patients with stage III-IV lung cancer without brain metastasis, colorectal cancer without liver metastasis, and breast cancer without lung metastasis were enrolled. The baseline imaging data and other clinical information were systematically collected, and the enrolled patients were assigned to the high-risk group and the low-risk group according to the radiomics prediction model. The radiomics prediction performance of the previously established metastatic target organ/primary lesion fusion radiomics model for tumor metastasis was regularly followed up and prospectively verified.

Inclusion criteria

  1. ECOG performance status score 0-2;
  2. Histologically or cytologically confirmed stage III-IV NSCLC;
  3. If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR/ALK/ROS1/KRAS/MET) should be performed;
  4. Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR/CT for colorectal cancer, and chest CT for breast cancer);
  5. No target organ metastasis on baseline imaging (no brain/liver/lung metastasis for lung cancer/colorectal cancer/breast cancer, respectively);
  6. Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up;
  7. Regular follow-up during and after treatment;
  8. Life expectancy ≥6 months;

Exclusion criteria

Exclusion Criteria:

  1. Patients with indeterminate pathological type;
  2. Patients without baseline imaging data before treatment;
  3. Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer/colorectal cancer/breast cancer corresponding to brain/liver/lung metastasis);
  4. patients who cannot or refuse to receive regular imaging follow-up;
  5. Combined history of other malignant tumors;
  6. Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; ,
  7. Lactating or pregnant women;
  8. Receiving other long-term medications that may affect disease progression as assessed by a physician.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
166 participants (estimated)
Patient registry
No

Groups and cohorts

  • High risk group

    This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.

  • Low risk group

    This is a observational study, patients will be assigned to high-risk or low-risk groups (according to a radiomics model) by the investigators. Both the patients and the treating physicians will be blinded to this procedure. No interventions excluding standard treatment procedure executed by the treating physicians.

06

What researchers measure

Primary outcomes

  1. brain metastasis-free survival, BMFS

    All patients were followed up regularly for at least 3 years. brain metastasis-free survival (BMFS) between the high-risk group and the low-risk group during follow-up was the primary endpoint. log-rank method was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) of brain metastases between the two groups. If the hazard ratio was less than 0.75 and the upper limit of the 95% confidence interval was less than 1, the study was considered to have met the prespecified end point.

    Time frame: from enrollment to follow-up.

Secondary outcomes

  1. 1-year/2-year/3-year BMFS rate

    1-year/2-year/3-year brain metastasis-free survival rate

    Time frame: 1-year/2-year/3-year from enrollment

  2. progression free survival

    From date of treatment start until the date of progression or the date of death due to any cause, evaluated according to RECIST 1.1 criteria,

    Time frame: Up to 5 years

  3. overall survival

    From date of treatment start to any cause death or last follow-up.

    Time frame: From date of treatment start until the date of death from any cause or censored at the last day that the subjects are documented to be alive, whichever came first, assessed up to 5 years

07

Study locations

2 of 2 sites recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
    Recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, China
    Recruiting
08

References and documents

Publications

  • Chu X, Gong J, Yang X, Ni J, Gu Y, Zhu Z. A "Seed-and-Soil" Radiomics Model Predicts Brain Metastasis Development in Lung Cancer: Implications for Risk-Stratified Prophylactic Cranial Irradiation. Cancers (Basel). 2023 Jan 2;15(1):307. doi: 10.3390/cancers15010307. PubMed 36612303 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06202404
Lead sponsor
Fudan University
Responsible party
Zhengfei Zhu (Professor, Fudan University) — Principal investigator
First posted
Jan 11, 2024
Start date
Jan 1, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 9, 2024

Study contacts

Xiao Chu
Contact
chuxiao@sibs.ac.cn
15821383376

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion